VAGULIENĖ, N. THE PEMBREIZH MULTICENTER REAL-LIFE COHORT STUDY: FIRST LINE PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER PATIENTS WITH PD-L1 ≥50%. Pulmonology and allergology, v. 4, n. 2, p. 164-167, 17 Sep. 2020.